Abstract
Regorafenib, an oral multi-kinase inhibitor, has been approved for the treatments of several malignancies. Unlike traditional cytotoxic chemotherapeut......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
